Trial Profile

Phase I study of TMP-301 in healthy volunteers

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 16 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HTL 0014242 (Primary)
Indications Cocaine-related disorders; Substance-related disorders
Focus Adverse reactions

Most Recent Events

01 Apr 2024 According to a Nxera Pharma Co., Ltd. media release, Sosei Heptares name changed to Nxera Pharma Co., Ltd.
05 Jan 2023 New trial record
04 Jan 2023 According to a Tempero Bio media release, the company recently been awarded a grant expected to total $5.3 million over two years from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health to support phase 1 studies.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com